LeMaitre Vascular (NASDAQ:LMAT) Announces Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• LeMaitre Vascular reported earnings of $0.60 per share, exceeding expectations by $0.03, with a year-over-year revenue increase of 15%.
• The company's stock rose by 1.5% to $85.60, following the earnings release, with a market capitalization of $1.93 billion.
• Insider activity showed CEO George W. Lemaitre sold 4,399 shares, reducing his stake by 0.24%, while institutional investors own 84.64% of the company.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) posted its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.03, Zacks reports. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same period last year, the company earned $0.52 EPS. LeMaitre Vascular's revenue for the quarter was up 15.0% compared to the same quarter last year. LeMaitre Vascular updated its Q3 2025 guidance to 0.540-0.590 EPS and its FY 2025 guidance to 2.230-2.370 EPS.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $1.98 on Friday, reaching $92.28. The company had a trading volume of 149,596 shares, compared to its average volume of 146,164. The stock has a market capitalization of $2.09 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.79. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a quick ratio of 13.83, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm's 50 day moving average price is $83.35 and its 200 day moving average price is $86.65.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is 38.83%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several analyst reports. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research note on Wednesday. Cantor Fitzgerald boosted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $98.00.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. This trade represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 200,000 shares of company stock worth $17,907,857. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. grew its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares in the last quarter. Strs Ohio purchased a new stake in LeMaitre Vascular in the first quarter worth about $168,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LeMaitre Vascular by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock worth $1,013,000 after acquiring an additional 539 shares in the last quarter. Jane Street Group LLC increased its position in LeMaitre Vascular by 738.7% during the 1st quarter. Jane Street Group LLC now owns 20,096 shares of the medical instruments supplier's stock valued at $1,686,000 after purchasing an additional 17,700 shares during the period. Finally, Intech Investment Management LLC increased its position in LeMaitre Vascular by 116.6% during the 1st quarter. Intech Investment Management LLC now owns 20,967 shares of the medical instruments supplier's stock valued at $1,759,000 after purchasing an additional 11,288 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.